Literature DB >> 9296186

Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms.

D F Kallmes1, M H Kallmes.   

Abstract

PURPOSE: To calculate the incremental cost-utility ratio for routine angiography performed during surgery for ruptured cerebral aneurysms.
METHODS: Decision-tree and Markov analyses based on a cohort simulation were used to determine the incremental cost-utility ratio of routine intraoperative angiography versus no angiography. Input data from the literature were estimated for the following variables: frequency of unexpected aneurysmal rests and branch artery occlusions; annual rate of rehemorrhage of partially clipped aneurysms; prevalence of clinically relevant infarction resulting from branch artery occlusion; efficacy of clip repositioning; morbidity associated with intraoperative angiography; morbidity and mortality associated with aneurysmal rehemorrhage; sensitivity of intraoperative angiography for aneurysmal rests; and costs of intraoperative angiography, added duration of surgery, ischemic cerebral infarction, aneurysmal rehemorrhage, and rehabilitation. Sensitivity analyses were performed for all relevant input variables. A societal perspective was used, and cost-utility ratios less than $50000/quality-adjusted life years (QALY) gained were considered acceptable.
RESULTS: Baseline input variables resulted in an acceptable cost-utility ratio for routine intraoperative angiography ($19000/QALY). The input variables with greatest influence on the cost-utility ratio were frequency of branch artery occlusions, angiographic morbidity, and cost of angiography. However, the cost-utility ratio remained acceptable even over wide ranges of these input variables. Frequency of unexpected partially clipped aneurysms, efficacy of clip repositioning, and costs of stroke, rehemorrhage, and rehabilitation had relatively little impact on the analysis.
CONCLUSION: Routine intraoperative angiography is cost-effective if performed in a manner consistent with low morbidity in a patient cohort harboring at least some unexpected branch artery occlusions that, if uncorrected, would result in clinically relevant cerebral infarctions.

Entities:  

Mesh:

Year:  1997        PMID: 9296186      PMCID: PMC8338130     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  6 in total

1.  Effects of Radiation Exposure on the Cost-Effectiveness of CT Angiography and Perfusion Imaging in Aneurysmal Subarachnoid Hemorrhage.

Authors:  J Ivanidze; R A Charalel; I Shuryak; D Brenner; A Pandya; O N Kallas; K Kesavabhotla; A Z Segal; M S Simon; P C Sanelli
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-12       Impact factor: 3.825

2.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 3.  The working road map in a neurosurgical Hybrid Angio-Surgical suite------ development and practice of a neurosurgical Hybrid Angio-Surgical suite.

Authors:  Zeguang Ren; Shuo Wang; Kaya Xu; Maxim Mokin; Yuanli Zhao; Yong Cao; Jia Wang; Hancheng Qiu; Siviero Agazzi; Harry van Loveren; Jizong Zhao
Journal:  Chin Neurosurg J       Date:  2018-03-22

4.  Cost-effectiveness of CT angiography and perfusion imaging for delayed cerebral ischemia and vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  P C Sanelli; A Pandya; A Z Segal; A Gupta; S Hurtado-Rua; J Ivanidze; K Kesavabhotla; D Mir; A I Mushlin; M G M Hunink
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-08       Impact factor: 3.825

5.  Work-in-progress toward incorporating patients' preferences in practice guidelines for imaging aneurysmal subarachnoid hemorrhage.

Authors:  Pina C Sanelli; Rachel L Gold; Edward D Greenberg; Melissa B Reichman; Igor Ugorec; Alan Z Segal; Matthew Fink
Journal:  Acad Radiol       Date:  2009-05       Impact factor: 3.173

Review 6.  Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.